Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD

Inclusion Criteria: * Adult male or female patients aged ≥40 years with stable moderate-to-severe COPD according to the GOLD Guidelines classification (grades II and III): forced expiratory volume in 1 second (measured between 10 to 15 minutes post-inhalation of 400 μg of salbutamol) is 30%≤FEV1\<80% of the predicted normal value * Patients naïve to both study inhaler devices, Genuair® and Breezhaler®, for at least 2 years * Agreement to participate and voluntarily sign the informed consent form Exclusion Criteria: * Patients with other clinically significant uncontrolled chronic diseases, particularly body malformations or diseases affecting coordination and/or motor system * Patients unable to read product package instructions and answer patient reported questionnaires (PASAPQ) * Patients with any other serious or uncontrolled mental health problems * Patients currently participating in other randomised clinical studies * Patients with COPD exacerbation within 6 weeks before Visit 1 and patient hospitalised for COPD exacerbation within 3 months prior to Visit 1 * Patients with any other conditions that, in the investigator's opinion, might indicate the patient to be inappropriate for the study * Patient likely to be uncooperative